Alendronate in the treatment of Paget's disease of bone

International Journal of Clinical Practice, Supplement

Volumn , Issue 101, 1999, Pages 62-66

  Reid, I R ^a   Siris, E ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; ETIDRONIC ACID;

ADVERSE DRUG REACTION; ALKALINE PHOSPHATASE BLOOD LEVEL; AUSTRALIA AND NEW ZEALAND; BONE DEFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; HUMAN; MORPHOMETRICS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSSIFICATION; OSTEOLYSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; STATISTICAL ANALYSIS; UNITED KINGDOM; UNITED STATES; ARTICLE; COMPARATIVE STUDY; FEMALE; LONG TERM CARE; MALE; PATHOLOGY; TREATMENT OUTCOME;

ALENDRONATE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LONG-TERM CARE; MALE; OSTEITIS DEFORMANS; TREATMENT OUTCOME;

EID: 33749196167     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (24)

1. Sins ES. Paget's disease of bone. In: Favus MJ, ed. Primer on the metabolic bone disease and disorders of bone metabolism. New York, Raven Press, 1993: 375-384.
2. Bone HG, KleereKoper M. Paget's disease of bone. J Clin Endocrinol Metab 1992; 75: 1179-1182.
3. Cantrill JA, Anderson DC. Treatment of Paget's disease of bone. Clin Endocrinol 1990; 32: 507-518.
4. Fleisch H. Bisphosphonates in osteoporosis: An introduction. Osteoporosis Int 1993; 3(suppl 3): S3-S5.
5. Boyce BF, Smith L, Fogelman I et al. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1984; 1: 821-824.
6. Weinstein RS. Focal mineralization defect during disodium etidronate treatment of calcinosis. Calc Tiss Int 1982; 34: 244-248.
7. Hosking DJ. Advances in the management of Paget's disease of bone. Drugs 1990; 40: 829-840.
8. Kantrowitz FG, Byrne MH, Schiller AL et al. Clinical and biochemical effects of diphosphonate in Paget's disease of bone. Arthritis Rheum 1975; 18: 407.
9. Canfield R, Rosner W, Skinner J et al. Diphosphonate therapy of Paget's disease of bone. J Clin Endocrinol Metab 1977; 44: 96-106.
10. Harinck HIJ, Papapoulos SE, Blanksma HJ et al. Paget's disease of bone; Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). BMJ 1987; 295: 1301-1305.
11. Gertz BJ, Holland SD, Kline WF et al. Clinical pharmacology of alendronate sodium. Osteoporosis Int 1993; 3(suppl 3): S13-S16.
12. Rodan GA, Seedor JG, Balena R. Preclinical pharmacology of alendronate. Osteoporosis Int 1993; 3(suppl 3): S7-S12.
13. Balena R, Toolan BC, Shea M et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993: 92: 2577-2586.
14. Sato M, Grasser W, Endo N et al. Bisphosphonate action: Alendronate localization in rat bone and effects of osteoclast ultrastructure. J Clin Invest 1991; 88: 2095-2105.
15. O'Doherty DP, Bickerstaff DR, Mccloskey EV et al. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Min Res 1990: 5: 483-491.
16. Adami S, Mian M, Gatti P et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone 1994; 15: 415-417.
17. Filipponi P, Pedetti M, Beghe F et al. Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed. Bone 1994; 15: 261-267.
18. Pedrazzoni M, Palummeri E, Ciotti G et al. Short-term effects on bone and mineral metabolism of 4-amino-hydroxybutylidene-1, 1-diphosphonate (ABDP) in Paget's disease of bone. Bone Miner 1989; 7: 301-307.
19. Adami S, Zamberlan N, Mian M et al. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyper-parathyroidism and Paget's disease of bone. Bone Min 1994; 25: 75-82.
20. Adami S, Salvagno G, Guarrera G et al. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calc Tiss Int 1986; 39: 226-229.
21. Schenk R, Merz WA, Muhlbauer R et al. Effect of EHDP and CI2MDP on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calc Tiss Res 1973; 11: 196-214.
22. Siris E, Weinstein RS, Altman R et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996; 81: 961-967.
23. Reid IR, Nicholson GC, Weinstein RS et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. Am J Med 1996; 171: 341-348.
24. Gray RE, Yates AJ, Preston CJ et al. Duration of effect of oral diphosphonate therapy in Paget's disease of bone. QJM 1987; 64: 755-767.